Browse Patents by Year
2021 Patents
- Compound Having KDM5 Inhibitory Activity And Pharmaceutical Use Thereof. WO2021/010492.
- Plasma Kallikrein Inhibitors. WO2021/028645.
- Plasma Kallikrein Inhibitors. WO2021/028649.
Previous Years
-
2020
- Rho Kinase Inhibitors and Compositions and Methods of Use Thereof. WO2020/264405.
- Novel Compounds And Pharmaceutical Compositions Thereof For The Treatment Of Hepatitis B. WO2020/239656.
- Pyridopyrimidines Derivatives As P2X3 Inhibitors. WO2020/239953.
- Amino Quinazoline Derivatives As P2X3 Inhibitors. WO2020/239952.
- Amino Quinazoline Derivatives As P2X3 Inhibitors. WO2020/239951.
- Inhibitor Compounds. WO2020/212697.
- Heterocyclic Compounds as RET Kinase Inhibitors. WO2017/178844.
- Heterocyclic Compounds as RET Kinase Inhibitors. WO2017/178845.
- PCSK9 Inhibitors and Methods of Use Thereof. WO2020/150473.
- Pyridazinone Compounds And Uses Thereof. WO2020/097266.
- Pyridazinone Compounds And Uses Thereof. WO2020/097265.
- Pyridazinone Compounds And Uses Thereof. WO2020/097258.
- Novel Compounds as NADPH Oxidase Inhibitors. WO2020/065048.
- Indane Derivatives For Use In The Treatment Of Bacterial Infection. WO2020/064173.
- Indane Derivatives For Use In The Treatment Of Bacterial Infection. WO2020/064174.
- Indane Derivatives For Use In The Treatment Of Bacterial Infection. WO2020/064175.
- Cinnoline Compounds And For The Treatment Of HPK1-Dependent Disorders Such As Cancer. WO2020/069402.
- Spirocyclic 2,3-Dihydro-7-Azaindole Compounds And Uses Thereof. WO2020/061377.
- Heterocyclic Substituted Ureas, for use Against Cancer. WO2020/030925.
- Isoquinoline Compounds and Uses Thereof Genentech (with CRL). WO2020/023560.
- Naphthyridine Compounds and Uses Thereof Genentech (with CRL). WO2020/023551.
- Tyrosine Amide Derivatives as Rho- Kinase Inhibitors Chiesi (with CRL). WO2020/016129.
-
2019
- Azaindole Derivatives As Rho- Kinase Inhibitors. WO2019/238628.
- Substituted Imidazopyridines As Inhibitors of Plasma Kallikrein And Uses Thereof. WO2019/178129.
- Non-Fused Thiophene Derivatives And Their Uses. WO2019/154956.
- Non-Fused Thiophene Derivatives And Their Uses. WO2019/154953.
- Fused Thiophene Derivatives And Their Uses. WO2019/154950.
- Fused Thiophene Derivatives And Their Uses. WO2019/154949.
- Pyrazolopyrimidine Compoinds as JAK Inhibitors. WO2019/139714.
- Pyrimidine Derivatives And Their Use Use For The Treatment Of Cancer. WO2019/122932.
- Azaindole Derivatives As Rho-Kinase Inhibitors. WO2019/121406.
- Oxadiazole Derivatives As Rho-Kinase Inhibitors. WO2019/121233.
- Meta Tyrosine Derivatives As Rho-Kinase Inhibitors. WO2019/121223.
- Heterocyclyl Substituted Pyrrolopyridines That Are Inhibitors Of The CDK12 Kinase. WO2019/058132.
- Vasopressin Receptor Antagonists And Products And Methods Related Thereto. WO2019/050988.
- Tyrosine Analogues Derivatives As Rho- Kinase Inhibitors. WO2019/048479.
- Compounds And Compositions For IRE1 Inhibition. WO2019/046711.
- New Substituted Azaindoline Derivatives As NIK Inhibitors. WO2019/008011.
-
2018
- Thiophene Derivatives as Antiviral Agents. WO2018/122317.
- (4-(([1,2,4]Triazolo[4,3-A]Pyridine-6-Yl)Oxy)-1,2,3,4-Tetrahydronaphthalen-1-Yl) Ureido Derivatives As Anti-Inflammatory P38 Mapk Inhibitors For Treating Diseases Of The Respiratory Tract. WO2018/224423.
- 1-(2-Azaspiro[3.3]Heptan-6-Yl)-5,6-Dihydro-4h-Benzo[F][1,2,4]Triazolo[4,3-A][1,4]Diazepine Derivatives As V1a Receptor Antagonists For Treating Neuropsychological Disorders. WO2018/226769.
- Compounds Useful As RET Inhibitors. WO2018/189553.
- Isoquinolines as Inhibitors of HPK1. WO2018/183964.
- Isoindolinone Inhibitors of the Mdm2-P53 Interaction and Process for Making Them. WO2018/178691.
- Naphthyridines as Inhibitors of HPK1. WO2018/183956.
- Chemical Compounds as Antibiotics. WO2018/172423.
- Azaindoles as Inhibitors of HPK1. WO2018/167147.
- Tyrosine Amide Derivatives as Rho-Kinase Inhibitors. WO2018/138293.
- Bicyclic Dihydropyrimidine-Carboxamide Derivatives as Rho-Kinase Inhibitors. WO2018/115383.
- Oxadiazolones as Transient Receptor Potential Channel Inhibitors. WO2018/096159.
- Pyridazine Derivatives as RORc Modulators. WO2018/083105.
- 8-(Azetidin-1-Yl)-[1,2,4]Triazolo[1,5-A]Pyridinyl Compounds, Compositions and Methods of Use Thereof. WO2018/046409.
- Hydroxyquinolinone Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO2018/011090.
- Cyanoindoline Derivatives as NIK Inhibitors. WO2018/002219.
- Heteroaromatic Derivatives as NIK Inhibitors. WO2018/002217.
-
2017
- Heteroaryl Estrogen Receptor Modulators and Uses Thereof. WO/2017/216279.
- Heterocyclic Compounds for Use in the Treatment of a Disease in Which HNE Is Implicated. WO/2017/207433.
- Novel Compounds. WO/2017/207432.
- Imidazolone Compounds as Human Neutrophil Elastase Inhibitors. WO/2017/207430.
- Crystal of Quinoline Derivative. WO/2017/199903.
- Pyrazole Derivatives, Compositions And Therapeutic Use Thereof. WO/2017/191098.
- Chemical Compounds as Inhibitors of Kinase Activity. WO/2017/137535.
- New 6-Membered Heteroaromatic Substituted Cyanoindoline Derivatives as NIK Inhibitors. WO/2017/125534.
- New Substituted Cyanoindoline Derivatives as NIK Inhibitors. WO/2017/125530.
- 1-(3-Tert-Butyl-2h-Pyrazol-5-Yl Or 5-Tert-Butyl-Isoxaol-3-Yl)-3-(4-([1,2,4]Triazolo[4,3-A]Pyridin-6-Yloxy)-1,2,3,4-Tetrahydro-Naphthalenyl) Urea Derivatives and Their Use as P38 Mapk Inhibitors. WO/2017/108738.
- 1-(3-Tert-Butyl-Phenyl)-3-(4-([1,2,4]Triazolo[4,3-A]Pyridin-6-Yloxy)-1,2,3,4-Tetrahydro- Naphthalen-1-Yl)-Urea Derivatives and Their Use as P38 Mapk Inhibitors. WO/2017/108737.
- N-[3-(3-{4-[[1,2,4]Triazolo[4,3-A]Pyridin-6-Yloxy]-1,2,3,4-Tetrahydro-Naphthalen-1-Yl} -Ureido)-Phenyl]-Methanesulfonamide Derivatives and Their Use as P38 Mapk Inhibitors. WO/2017/108736.
- Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2017/093208.
- Isoindolinone Inhibitors of the Mdm2-P53 Interaction Having Anticancer Activity. WO/2017/055860.
- Isoindolinone Inhibitors of the Mdm2-P53 Interaction Having Anticancer Activity. WO/2017/055859.
- Tricyclic PI3k Inhibitor Compounds and Methods of Use. WO/2017/042182.
- Aryl Sultam Derivatives as RORc Modulators. WO/2017/005900.
- Aryl Sultam Derivatives as RORc Modulators. WO/2017/005668.
- Benzoxazepin Oxazolidinone Compounds and Methods of Use. WO/2017/001645.
- Benzoxazepin Oxazolidinone Compounds and Methods of Use. WO/2017/001658.
-
2016
- Aminoester Derivatives Useful in the Treatment of COPD. WO/2016/193240.
- Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2016/193241.
- Aminoester Derivatives. WO/2016/193244.
- Heterocyclic Estrogen Receptor Modulators and Uses Thereof. WO/2016/189011.
- Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2016/179550.
- Histone Deacetylase Inhibitors and compositions and Methods of Use Thereof. WO/2016/179554.
- Pyridazine Derivatives as RORc Modulators. WO/2016/177686.
- Pyridazine Derivatives as RORc Modulators. WO/2016/177710.
- Pyridazine Derivatives as RORc Modulators. WO/2016/177760.
- Aminoester Derivatives. WO/2016/177849.
- Amino-substituted Heterocyclic Derivatives as Sodium Channel Inhibitors. WO/2016/170009.
- Amido Thiadiazole Derivatives as NADPH Oxidase Inhibitors. WO/2016/098005.
- Estrogen Receptor Modulators and Uses Thereof. WO/2016/0304450.
- Pyrazolopyridazines and Methods for Treating Retinal-Degenerative Diseases and Hearing Loss Associated with Usher Syndrome. WO/2016/0272647.
- Antibacterial Thiazolecarboxylic Acids. WO/2016/0272601.
- Triazolopyridine Compounds and Methods of Use Thereof. WO/2016/139212.
- Preparation of thiazole sulfonamides as metallo-β-lactamase inhibitors for the treatment and prevention of bacterial infections in combination with β-lactam antibiotics. GB 2533136.
- Tetrahydro-Pyrido[3,4-B]Indole Estrogen Receptor Modulators and Uses Thereof. WO/2016/097072.
- Estrogen Receptor Modulators and Uses Thereof. WO/2016/097071.
- Novel Compounds. WO/2016/096638.
- New Compounds as Nik Inhibitors. WO/2016/062792.
- New Pyrazole Derivatives as Nik Inhibitors. WO/2016/062791.
- New Pyrazolopyrimidine Derivatives as Nik Inhibitors. WO/2016/062790.
- New Thienopyrimidine Derivatives as Nik Inhibitors. WO/2016/062789.
-
2015
- Tetrahydrotriazolopyrimidine Derivatives, Pharmaceutical Compositions Containing the Same and Uses. WO/2015/189362.
- Novel Compounds. WO/2015/188866.
- Histone Deacetylase Inhibitors and Compositions and Methods of use Thereof. WO/2015/187542.
- Carbamate Derivatives which are both Phosphodiesterase 4 (PDE4) Enzyme Inhibitors and Muscarinic M3 Receptor Antagonists. WO/2015/185650.
- Aminoester Derivatives. WO/2015/185649.
- 3,5-Dichloro,4-(3,4-(Cyclo-)Alkoxyphenyl)-2-Arbonyloxy)Ethyl)Pyridine Derivatives as PDE -4 Inhibitors. WO/2015/185130.
- 3,5-Dichloro,4-(3,4-(Cyclo-)Alkoxyphenyl)- 2-Carbonyloxy)Ethyl)Pyridine Derivatives as PDE-4 Inhibitors. WO/2015/185128.
- 5-Chloro-2-Difluoromethoxyphenyl Pyrazolopyrimidine Compounds which are Jak Inhibitors.WO/2015/177326.
- Benzene Sulfonamide Derivatives and their use as RORc Modulators. WO/2015/177325.
- 6-Substituted Imidazo[1,2-A]Pyrazinecarboxamides and Use Thereof. WO/2015/165933.
- Imidazo[1,2-A] Pyridines as Stimulators of Soluble Guanylate Cyclase for Treating Cardiovascular Disease. WO/2015/165931.
- Fused Imidazole Compounds. WO/2015/115673.
- (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase I Inhibitors. WO/2015/110826
- Aryl Sultam Derivatives as RORc Modulators. WO/2015/104356.
- Aryl Sultam Derivatives as RORc Modulators. WO/2015/104354.
- Thiazolopyridine Compounds, Compositions and Their Use as Tyk2 Kinase Inhibitors. WO/2015/091584.
- Tetrahydrotriazolopyrimidine Derivatives as Human Neutrophil Elastase Inhibitors. WO/2015/091281.
- Benzhydryl Derivatives for the Treatment of Respiratory Diseases. WO/2015/082619.
- Heteroaryl Derivatives for the Treatment of Respiratory Diseases. WO/2015/082616.
- Heteroaryl-Ether Fused Azadecalin Glucocorticoid Receptor Modulators. WO/2015/077537.
- New 3-(1H-Pyrazol-4-Yl)-1H-Pyrrolo[2,3-c]Pyridine Derivatives as NIK Inhibitors. WO/2015/044269.
- New 1-(4-Pyrimidinyl)-1H-Pyrrolo[3,2-c]Pyridine Derivatives as NIK Inhibitors. WO/2015/044267.
- Triazolopyridine Compounds, Compositions and Methods of Use Thereof. WO/2015/032286.
-
2014
- Azaindazole Compounds as Inhibitors of T790M-Containing EGFR Mutants. WO/2014/210354.
- Antibacterial Thiazolecarboxylic Acids. WO/2014/198849.
- Kinase Inhibitors. WO/2014/195402.
- Kinase Inhibitors. WO/2014/195400.
- Derivatives of (1, 2, 4) Triazolo (4, 3–A) Pyridine as p38-MAP Kinase Inhibitors. WO/2014/194956.
- 3-(2-Aminopyrimidin-4-yl)-5-(3-Hydroxypropynyl)-1H-Pyrrolo[2,3-C]Pyridine Derivatives as NIK Inhibitors for the Treatment of Cancer. WO/2014/174021.
- Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159224.
- Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159218.
- Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159214.
- Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159210.
- Aryl Sulfamide and Sulfamate Derivatives as RORc Modulators. WO/2014/140059.
- Novel Compounds. WO/2014/095700.
- Benzyl Sulfonamide Derivatives as Rorc Modulators. WO/2014/090712.
- Benzyl Sulfonamide Derivatives as Rorc Modulators. WO/2014/090710.
- Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2014/086927.
- Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2014/086924.
- Phenylethylpyridine Derivatives as PDE4-Inhibitors. WO/2014/086855.
- Phenylethylpyridine Derivatives as PDE4-Inhibitors. WO/2014/086852.
- Phenylethylpyridine Derivatives as PDE4-Inhibitors. WO/2014/086849.
- Aminopyrimidine Compounds as Inhibitors of T790M Containing EGFR Mutants. WO/2014/081718.
- Tricyclic Compounds for Use in the Treatment and/or Control of Obesity. WO/2014/071369.
- Tricyclic Compounds and Methods of Making and Using Same. WO/2014/071363.
- Pyrazolopyridazines and Methods for Treating Retinal-Degenerative Diseases and Hearing Loss Associated With Usher Syndrome. WO/2014/066836.
- Pyrazolopyridazines and Methods for Treating Retinal-Degenerative Diseases and Hearing Loss Associated With Usher Syndrome. WO/2014/066835.
- Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. WO/2014/048939.
- Dioxino- and Oxazin-[2,3-D]Pyrimidine Pi3k Inhibitor Compounds and Methods of Use. WO/2014/033196.
- Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/014900.
- Fused Triazole Derivatives as Gamma Secretase Modulators. WO/2014/012614.
- Aryl Sultam Derivatives as RORc Modulators. WO/2014/009447.
- Inhibition of Enzymes. WO/2014/009425.
-
2013
- Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators. WO/2013/177559.
- Pyrazole Aminopyrimidine Derivatives as LRRK2 Modulators for use in the Treatment of Parkinson's Disease. WO/2013/164323.
- Pyrazole Aminopyrimidine Derivatives as LRRK2 Modulators. WO/2013/164321.
- Phenyl Heterocycloalkyl Glucocorticoid Receptor Modulators. WO/2013/130420.
- Tricyclic Sulfonamide Compounds and Methods of Making and Using Same. WO/2013/109739.
- Tricyclic Sulfonamide Compounds and Methods of Making and Using Same. WO/2013/109735.
- Kinase Inhibitors. WO/2013/083606.
- Kinase Inhibitors. WO/2013/083604.
- Derivatives of 4-Hydroxy-1,2,3,4-Tetrahydronaphthalen-1-yl Urea and Their Use in the Treatment of, Inter Alia, Diseases of the Respiratory Tract. WO/2013/083206.
- Aminopyrimidine derivatives as LRRK2 modulators WO/2013/079505
- 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase LRRK2 modulators for the treatment of Parkinson's Disease WO/2013/079495
- 2-phenylaminopyrimidine derivatives as kinase LRRK2 modulators for the treatment of Parkinson's Disease WO/2013/079494
- Aminopyrimidine derivatives as LRRK2 modulators WO/2013/079493
- Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. WO/2013/045461
- Fsh receptor antagonists. WO/2013/041461
- Fsh receptor antagonists. WO/2013/041458
- N-piperidin-4-yl derivatives. WO/2013/041457
- Tetrahydrotriazolopyrimidine Derivatives as Human Neutrophil Elastase Inhibitors. WO/2013/037809.
- Tricyclic Heterocyclic Compounds, Compositions and Methods of Use Thereof as Jak Inhibitors. WO/2013/007768.
- Fused Tricyclic Compounds for Use as Inhibitors of Janus Kinases. WO/2013/007765.
-
2012
- Compounds having muscarinic receptor antagonist and beta-2 andrenergic receptor agonist activity. WO/2012/168359
- Compounds having muscarinic receptor antagonist and beta-2 andrenergic receptor agonist activity. WO/2012/168349
- Tricyclic pyrazole sulfonamide compounds and methods of making and using same. WO/2012/154679.
- Tricyclic sulfonamide compounds and methods of making and using same. WO/2012/154678.
- Partially saturated tricyclic compounds and methods of making and using same. WO/2012/154676.
- Pyrazolopyridines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome. WO/2012/148994
- Novel compound useful for the treatment of degenerative and inflammatory diseases. WO/2012/146659
- Novel compound useful for the treatment of degenerative and inflammatory diseases. WO/2012/146657.
- Pyrimidine cyclohexyl glucocorticoid receptor modulators. WO/2012/129074.
- Benzoxapin compounds selective for PI3K P110 delta and methods of use. WO/2012/126901.
- Heterocyclic compounds as PI3 kinase Inhibitors. WO/2012/107465.
- Tetrazole Compounds and Methods of Making and Using Same. WO/2012/103333.
- Histone deacetylase inhibitors and compositions and methods of use thereof. WO/2012/103008.
- Tricyclic pyrazinone compounds, compositions and methods of use thereof as Janus Kinase inhibitors. WO/2012/085176.
- Tricyclic pi3k inhibitor compounds and methods of use. WO/2012/082997.
- Pyrazolopyridines and pyrazolopyridines and their use as Tyk2 inhibitors. WO/2012/066061.
- Pyrazole aminopyrimidine derivatives as LRRK2 modulators. WO/2012/062783
- Sulphonamide Compounds and Methods of Making and Using Same. WO/2012/051318.
- Bacteria topoisomerase II inhibiting 2-ethylcarbamoylamino-1,3-benzothiazol-5-yls. WO/2012/045124
- Azabenzothiazole compounds, compositions and methods of use. WO/2012/035039.
- Tricyclic Compounds and Methods of making and using same. WO/2012/012642.
- 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors. WO/2012/004287
-
2011
- Urea Derivatives and Their Therapeutic Use in the Treatment of, Inter Alia, Diseases of the Respiratory Tract. WO/2011/154738.
- Compounds. WO/2011/154678.
- Aminopyrimidine derivatives as LRRK2 modulators. WO/2011/151360.
- 3, 3-Disubstituted-( 8-Aza-Bicyclo [3.2.1] Oct-8-yl)-[5-(1H-Pyrazol-4-yl)-Thiophen-3-yl] Methanones as Inhibitors of 11 (Beta)-HSD1. WO/2011/135276.
- Preparation of 4H-1,2,4]triazolo[5,1-b]pyrimidin-7-one derivatives as CCR2b receptor antagonists. WO/2011/114148.
- Pyrimidine Derivatives and Their Use in the Treatment of Respiratory Diseases Such as COPD. WO/2011/110859.
- Pyrimidine Derivatives and Their Use in the Treatment of Respiratory Diseases Such as COPD. WO/2011/110858.
- Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions. WO/2011/104340.
- Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions. WO/2011/104338.
- Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions. WO/2011/104337.
- 3. 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - D] pyrimidines having MNKL/ MNK2 inhibiting activity for pharmaceutical compositions. WO/2011/104334.
- Crystalline Acid Addition Salts of (5R)-Enantiomer of Pioglitazone. WO/2011/098746.
- 1,2,4-triazine-4-amine derivatives. WO/2011/095625.
- New anti-malarial agents. WO/2011/086531.
- Tricyclic heterocyclic compounds, compositions and methods of use thereof. WO/2011/086053.
- 1,7 diazacarbazoles and their use in the treatment of cancer. WO/2011/073263.
- Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors. WO/2011/058113.
- Fused bicyclic pyrazole derivatives as kinase inhibitors. WO/2011/058112.
- Aminopurine derivatives as kinase inhibitors. WO/2011/058111.
- Quinoline and quinoxaline derivatives as kinase inhibitors. WO/2011/058110.
- Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors WO/2011/058109.
- Quinoline and quinoxaline derivatives as kinase inhibitors. WO/2011/058108.
- Sulphone Compounds and Methods of Making and Using Same. WO/2011/044506.
- Benzoxazepin Pi3k Inhibitor Compounds and Methods of Use. WO/2011/036284.
- Benzoxazepin Pi3k Inhibitor Compounds and Methods of Use. WO/2011/036280.
- Pharmaceutical compounds. WO/2011/033265.
- 4-Phenyl-piperidin-1-yl)-[5-1H-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use. WO/2011/033255.
- Enantiomeric Resolution Method. WO/2011/015868.
- Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurogenerative diseases. WO/2011/015573.
- Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurogenerative diseases. WO/2011/015572.
-
2010
- 5R-5-Deuterated Glitazones for Respiratory Disease Treatment. WO/2010/150014.
- Amido-isothiazole compounds and their use as inhibitors of 11beta-Hsd1 for the treatment of metabolic syndrome and related disorders. WO/2010/146338.
- Indole Derivatives as Ligands of Crth2 Receptors. WO/2010/142934.
- Janus Kinase Inhibitor Compounds and Methods. WO/2010/142752.
- Pyrazole oxadiazole derivatives as S1P1 agonists. WO/2010/142628.
- Bicyclic Pyrimidine Pi3k Inhibitor Compounds Selective for P110 Delta, and Methods of Use. WO/2010/138589.
- Bicyclic Indole-Pyrimidine Pi3k Inhibitor Compounds Selective for P110 Delta, and Methods of Use. WO/2010/136491.
- Fused bicyclic pyrazole derivatives as kinase inhibitors. WO/2010/133836.
- Pyridylurea Derivatives and Their Therapeutic Use. WO/2010/131030.
- Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives. WO/2010/123933.
- Compounds, compositions and methods comprising pyridazine sulphonamide derivatives. WO/2010/123822.
- Methods and means for treatment of osteoarthritis. WO/2010/115841.
- Preparation of triazines as phosphoinositide 3-kinase (PI3K) inhibitors. WO/2010/100405.
- Triazolopyridine Derivatives as P38 Map Kinase Inhibitors. WO/2010/094956.
- Pyrimidopyridazine Derivatives Useful as P38 Inhibitors. WO/2010/094955.
- Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation. WO/2010/094734.
- Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation. WO/2010/094733.
- Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation. WO/2010/094732.
- Fused pyridine and pyrazine derivatives as kinase inhibitors. WO/2010/092340.
- Dimeric Pyrrolopyrimidinedione and Its Use in Therapy of Respiratory Diseases. WO/2010/086638.
- Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient. WO/2010/071582.
- Pharmaceutical product comprising a muscarinic receptor antagonist and a B2-adrenoceptor agonist. WO/2010/071581.
- Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders. WO/2010/067102.
- Preparation of fused pyrazines as phosphoinositide 3-kinase (PI3K) inhibitors. WO/2010/052448.
- Compounds, compositions and methods comprising imidazole and triazole derivatives. WO/2010/033626.
- Thienopyrimidines for pharmaceutical compositions. WO/2010/023181.
- 2-hydroxy-ethanesulfonate salt. WO/2010/019099.
- Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. WO/2010/019098.
- Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient. WO/2010/019097.
- Heterocyclic compounds used in the treatment of diseases where enhanced M3 receptor activation is implicated. WO/2010/018352.
- Nitrogen containing heterocyclic compounds useful as bifunctional modulators of M3 receptors and beta-2 receptors. WO/2010/015792.
- Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2010/010190.
- Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2010/010189.
- Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2010/010188.
- [1, 2, 4] triazolo [1, 5-a] pyridines as JAK inhibitors. WO/2010/010184.
- Bicyclic heterocycles as Mek kinase inhibitors. WO/2010/003025.
- Isoindolone derivatives as Mek kinase inhibitors and methods of use. WO/2010/003022.
-
2009
- Triazolo JAK Inhibitor Compounds and Methods. WO/2009/155551.
- Diazacarbazoles as checkpoint kinase 1 inhibitors and their preparation and use in the treatment of cancer. WO/2009/151598.
- Diazacarbazoles as checkpoint kinase 1 inhibitors and their preparation and use in the treatment of cancer. WO/2009/151589.
- Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Βeta2-Adrenoceptor Agonist. WO/2009/139708.
- Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Second Active Ingredient. WO/2009/139707.
- Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents. WO/2009/138796.
- Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases. WO/2009/138794.
- Substituted quinazolines. WO/2009/138792.
- Substituted quinazolines as blood platelet lowering agents. WO/2009/138789.
- Substituted quinazolines. WO/2009/138788.
- Quinuclidine derivatives as muscarinic M3 receptor antagonists. WO/2009/138707.
- Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2009/135885.
- Compounds, compositions and methods comprising triazine derivatives. WO/2009/131958.
- Compounds, compositions and methods comprising oxadiazole derivatives. WO/2009/131957.
- Compounds, compositions and methods comprising triazole derivatives. WO/2009/131956.
- Compounds, compositions and methods comprising oxadiazole derivatives. WO/2009/131954.
- Compounds, compositions and methods comprising thiazole derivatives. WO/2009/131952.
- Compounds, compositions and methods comprising isoxazole derivatives. WO/2009/131951.
- High-throughput cell-based CFTR assay. WO/2009/131948.
- Compounds, compositions and methods comprising pyridazine derivatives. WO/2009/131947.
- Preparation of amido-thiophene compounds as 11β-HSD1 inhibitors. WO/2009/112845.
- 2-(9H-xanthen-9-yl)-oxazol Derivatives as M3 Muscarinic Receptor Antagonists for the Treatment of Asthma and Chronic Obstructive Lung Disease. WO/2009/098455.
- Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists. WO/2009/098453.
- Compounds. WO/2009/098448
- 5-Anilinoimidazopyridines and Methods of Use. WO/2009/085983.
- 8-Anilinoimidazopyridines and Their Use as Anti-Cancer and/or Anti-Inflammatory Agents. WO/2009/085980.
- Azaindolizines and Methods of Use. WO/2009/082687.
- Quinoxaline and quinoline derivatives as kinase inhibitors. WO/2009/081105.
- Triazole Oxadiazoles Derivatives. WO/2009/080663.
- Preparation of substituted amidothiophene derivatives for use as 11-beta-hsd1 inhibitors. WO/2009/074789.
- A substituted thieno-pyridinone kinase inhibitor. WO/2009/071901.
- Fused thiazole and thiophene derivatives as kinase inhibitors. WO/2009/071895.
- Purine Derivatives Useful as PI3 inhibitors. WO/2009/053716.
- Thienopyrimidines Derivatives Useful as PI3 inhibitors. WO/2009/053715.
- Triazolopyridine compounds and their use as ASK inhibitors. WO/2009/027283.
-
2008
- N-Substituted Azaindoles and Methods of Use. WO/2008/157179.
- Pharmaceutical Compounds. WO/2008/152394.
- Pharmaceutical Compounds. WO/2008/152390.
- Pharmaceutical Compounds. WO/2008/152387.
- Bicyclo [2.2.1] Hept-7-ylamine Derivatives and Their Use in the Treatment of Diseases and Conditions in which M3 Muscarinic Receptor Activity and Beta-Adrenergic Activity are Implicated. WO/2008/149110.
- Bicyclo [2.2.1] Hept- 2-ylamine Derivatives and Their Use. WO/2008/149053.
- Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms. WO/2008/142384.
- Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative and inflammatory diseases. WO/2008/138843.
- Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases. WO/2008/138842.
- 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases. WO/2008/129080.
- Pharmaceutical Compounds. WO/2008/125839.
- Pharmaceutical Compounds. WO/2008/125833.
- CFTR inhibitor compounds and uses thereof. WO/2008/121877.
- Antimicrobial compounds based upon 4-aminoquinoline as drugs, preservatives, and sterilants. WO/2008/117079.
- Use of N2-phenylamides as herbicides. WO/2008/110278.
- Quinolinone derivatives as parp and tank inhibitors. WO/2008/107478.
- New salt. WO/2008/096149.
- Combinations with a muscarinic receptor antagonist. WO/2008/096136.
- Nitrogen containing heterocyclic compounds useful as bifunctional modulators of M3 receptors and beta-2 receptors. WO/2008/096129.
- New chemical compounds. WO/2008/096127.
- Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. WO/2008/096126.
- 1-Aminomethyl-1-Phenyl-Cyclohexane Derivatives as DPP-IV Inhibitors. WO/2008/077597.
- Pyridine benzamides and pyrazine benzamides used as PKD inhibitors. WO/2008/074997.
- Aza-indolyl Compounds and Methods of Use. WO/2008/067481.
- Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2008/065199.
- Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2008/065198.
- Preparation of 4-Substituted 2-Amino-Benzo[4,5]Pyrimidine Derivatives. WO/2008/062013.
- Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2008/055959.
- Aza-Benzofuranyl Compounds and Methods of Use. WO/2008/024725.
- Aza-Benzothiophenyl Compounds and Methods of Use. WO/2008/024724.
- Nitrogen Containing Heterocyclic Compounds Useful as M3-Receptor Modulators. WO/2008/023157.
-
2007
- Antibacterial compositions. WO/2007/148093.
- Preparation of pteridine derivatives as cathepsin inhibitors.WO/2007/148064.
- Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in MCH-1 mediated diseases. WO/2007/141200.
- Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2007/138072.
- Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2007/131991.
- Pyrimidine Derivatives as PI3k Inhibitors. WO/2007/122410.
- Trisubstituted 1,2,4-triazoles. WO/2007/118903.
- Organic Compounds. WO/2007/115821.
- Compositions and Methods for Modulating Gated Ion Channels. WO/2007/115410.
- Compositions and Methods for Modulating Gated Ion Channels. WO/2007/115409.
- Azetidine Amino Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/090854.
- Enantiomers of Amino Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/090853.
- Amino Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/090852.
- Pyridine-, isoxazole, thiophenecarboxamide compounds having activity at the glycine transporter GlyT1 and uses thereof. WO/2007/080159.
- Condensed heterocyclic compounds useful as DPP-IV inhibitors. WO/2007/071738.
- Novel substituted pyrazinone derivatives for use in MCH-1 mediated diseases. WO/2007/071646.
- Use of pyrroloquinoline compounds to kill clinically latent microorganisms. WO/2007/054693.
- Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/045867.
- 1,5-Substituted Tetrazoles as Therapeutic Compounds. WO/2007/029021.
- EP2 receptor agonists. WO/2007/017687.
-
2006
- Tricyclic spiro derivatives as CRTH2 modulators. WO/2006/125784.
- Piperazine derivatives as GlyT1 inhibitors. WO/2006/094843.
- Acylated piperidines as glycine transporter inhibitors. WO/2006/094842.
- Preparation of acylated piperazines as glycine transporter inhibitors. WO/2006/094840.
- Substituted bis aryl and heteroaryl compounds as selective 5-HT2a antagonists. WO/2006/086705.
- Compounds which bind to the active site of protein kinase enzymes. WO/2006/072792.
- Oxygen containing heterocycles as glycine transporter inhibiting compounds. WO/2006/067437.
- Glycine transport inhibitors. WO/2006/067430.
- Glycine transport inhibitors. WO/2006/067423.
- Glycine transport inhibitors. WO/2006/067417.
- Glycine transport inhibitors. WO/2006/067414.
- Preparation of 4H-spiro[1,3]benzodioxine-2,4'-piperidine derivatives and related compounds. WO/2006/067224.
- Preparation of thienopyridine derivatives as potassium channel inhibitors for the treatment of arrhythmia and diabetes. WO/2006/061642.
- Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes. WO/2006/051311.
- 2, 6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin D2 receptor antagonists. WO/2006/044732.
- Pyrazolo[1,5-a]pyrimidine derivative. WO/2006/016715.
- Tetrahydronaphthalene derivatives as glucocorticoid receptor modulators. WO/2006/015870.
- Modified Pyrimidine Glucocorticoid Receptor Modulators.WO/2006/014394.
- Pyridinylamines and their preparations, pharmaceutical compositions and use for prophylaxis or treatment of various diseases. WO/2006/010637.
- Novel indazole carboxamides and their use. WO/2006/002434.
-
2005
- Furanopyrimidine compounds effective as potassium channel inhibitors. WO/2005/121149.
- Preparation of triazacyclopenta[b]naphthalene derivatives as modulators of glucocorticoid receptor. WO/2005/087769.
- Preparation of phenylindan amino acid derivatives as inhibitors of glycine transport. WO/2005/087708.
- EP2 receptor agonists. WO/2005/080367.
- Azadecalin Glucocorticoid Receptor Modulators. WO/2005/070893.
- Preparation of spiro(beta-carbolinepyrrolidines) and related compounds as growth hormone secretagogue receptor (GHSR) antagonists. WO/2005/048916.
- Novel Diazaspiroalkanes and Their Use for Treatment of CCR-8 Mediated Diseases. WO/2005/040167.
- Furan Derivatives as EP4 Receptor Antagonists. WO/2005/037812.
- Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases. WO/2005/026129.
- Imidazo[1,5-a] pyradine or imidazo[1,5-a] piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders. WO/2005/021545.
- The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders. WO/2005/021505.
- 5-HT2B Receptor Antagonists. WO/2005/012263.
-
2004
- Thienopyrimidine derivatives as potassium channel inhibitors. WO/2004/111057.
- Preparation of pyrazolo[1,5-a]pyrimidine derivatives as kinase inhibitors. WO/2004/081013.
- Pyrazolo[1,5-A] pyrimidine derivatives. WO/2004/076458.
- EP4 Receptor Antagonists. WO/2004/067524.
- Spirocyclic cyclohexane derivatives. WO/2004/043967.
-
2003
- Preparation of pesticidal pyridinecarboxamides. WO/2003/097605.
- 2-Oxazolamines and Their Use as 5-HT2B Receptor Antagonists. WO/2003/068226.
- Heteroaryl compounds useful as inhibitors of GSK-3. WO/2003/066629.
- Aryloxyphenyl and Arylsulfanylphenyl Derivatives. WO/2003/053942.
- Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity. WO/2003/020282.
- Preparation of 2-(benzoylamino)benzoic acid derivatives as modulators of the PPARalpha and PPARgamma receptors. WO/2003/004458.
-
2002
- Preparation of aryl-substituted N-hydroxy amides with sulfonamide linkages as HDAC inhibitors for treatment of proliferative conditions. WO/2002/030879.
- Novel pyridazine compounds for the treatment of diabetes. WO/2002/026743.
- Preparation of carbamic acid compounds comprising an ether linkage as HDAC inhibitors. WO/2002/026703.
- Carbamic acid compounds comprising an amide linkage as HDAC inhibitors. WO/2002/026696.